Do analysts rate TELO or IRD?

Opus Genetics has a consensus target price of $10.77, suggesting a potential upside of 185.58%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Opus Genetics 1 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.88

Does the media refer more to TELO or IRD?

In the previous week, Opus Genetics had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Opus Genetics and 2 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.94 beat Opus Genetics' score of 0.25 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Opus Genetics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TELO or SNDL?

SNDL has a consensus target price of $5.00, indicating a potential upside of 280.23%. Given SNDL's higher probable upside, analysts clearly believe SNDL is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SNDL 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer TELO or ELDN?

Eledon Pharmaceuticals has a consensus target price of $9.67, suggesting a potential upside of 152.00%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Eledon Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has higher earnings & valuation, TELO or ELDN?

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A Eledon Pharmaceuticals N/A N/A -$45.62M -$0.77 N/A

Is TELO or ELDN more profitable?

Eledon Pharmaceuticals' return on equity of -116.97% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -201.23% -172.71% Eledon Pharmaceuticals N/A -116.97% -41.91%

Do analysts prefer ALXO or TELO?

ALX Oncology presently has a consensus target price of $4.60, suggesting a potential upside of 130.58%. Given ALX Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe ALX Oncology is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, ALXO or TELO?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.49 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A

Is ALXO or TELO more profitable?

ALX Oncology's return on equity of -124.06% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% Telomir Pharmaceuticals N/A -201.23% -172.71%

Does the media refer more to ALXO or TELO?

In the previous week, ALX Oncology had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for ALX Oncology and 2 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.94 beat ALX Oncology's score of -0.03 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ORGO or TELO?

Organogenesis presently has a consensus price target of $5.75, indicating a potential upside of 153.86%. Given Organogenesis' higher possible upside, equities research analysts plainly believe Organogenesis is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to ORGO or TELO?

In the previous week, Organogenesis and Organogenesis both had 2 articles in the media. Telomir Pharmaceuticals' average media sentiment score of 0.94 beat Organogenesis' score of 0.63 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Telomir Pharmaceuticals (TELO) Competitors

$1.23 -0.02 (-1.21%)

As of 10:13 AM Eastern

Compare

TELO vs. IRD, SNDL, ELDN, ALXO, and ORGO

Should you buy Telomir Pharmaceuticals stock or one of its competitors? MarketBeat compares Telomir Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Telomir Pharmaceuticals include Opus Genetics (IRD), SNDL (SNDL), Eledon Pharmaceuticals (ELDN), ALX Oncology (ALXO), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry.

How does Telomir Pharmaceuticals compare to Opus Genetics?

Telomir Pharmaceuticals (NASDAQ:TELO) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Telomir Pharmaceuticals has higher earnings, but lower revenue than Opus Genetics. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
Opus Genetics	$14.20M	21.93	-$49.59M	-$1.33	N/A

In the previous week, Opus Genetics had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Opus Genetics and 2 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.94 beat Opus Genetics' score of 0.25 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Opus Genetics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.0% of Opus Genetics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Telomir Pharmaceuticals has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Telomir Pharmaceuticals has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Telomir Pharmaceuticals' return on equity of -201.23% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
Opus Genetics	-892.36%	-338.88%	-191.21%

Opus Genetics has a consensus target price of $10.77, suggesting a potential upside of 185.58%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Opus Genetics beats Telomir Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to SNDL?

Telomir Pharmaceuticals (NASDAQ:TELO) and SNDL (NASDAQ:SNDL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than SNDL. MarketBeat recorded 2 mentions for Telomir Pharmaceuticals and 1 mentions for SNDL. SNDL's average media sentiment score of 1.87 beat Telomir Pharmaceuticals' score of 0.94 indicating that SNDL is being referred to more favorably in the news media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Positive
SNDL	Very Positive

SNDL has a consensus target price of $5.00, indicating a potential upside of 280.23%. Given SNDL's higher probable upside, analysts clearly believe SNDL is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SNDL	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, SNDL has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

Telomir Pharmaceuticals has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
SNDL	-1.19%	-1.02%	-0.85%

Telomir Pharmaceuticals has higher earnings, but lower revenue than SNDL. SNDL is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
SNDL	$677.32M	0.50	-$11.29M	-$0.03	N/A

Summary

SNDL beats Telomir Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Eledon Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 2 mentions for Telomir Pharmaceuticals and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.89 beat Telomir Pharmaceuticals' score of 0.94 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Positive
Eledon Pharmaceuticals	Very Positive

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Eledon Pharmaceuticals has a consensus target price of $9.67, suggesting a potential upside of 152.00%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Telomir Pharmaceuticals has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Eledon Pharmaceuticals' return on equity of -116.97% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%

Summary

Eledon Pharmaceuticals beats Telomir Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

ALX Oncology presently has a consensus target price of $4.60, suggesting a potential upside of 130.58%. Given ALX Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe ALX Oncology is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

98.0% of ALX Oncology shares are held by institutional investors. 21.0% of ALX Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

ALX Oncology's return on equity of -124.06% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

In the previous week, ALX Oncology had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for ALX Oncology and 2 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.94 beat ALX Oncology's score of -0.03 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ALX Oncology has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Summary

ALX Oncology beats Telomir Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Organogenesis?

Organogenesis (NASDAQ:ORGO) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Organogenesis has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

Organogenesis has higher revenue and earnings than Telomir Pharmaceuticals. Organogenesis is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.52	$37.03M	-$0.19	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

In the previous week, Organogenesis and Organogenesis both had 2 articles in the media. Telomir Pharmaceuticals' average media sentiment score of 0.94 beat Organogenesis' score of 0.63 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

49.6% of Organogenesis shares are held by institutional investors. 18.8% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Telomir Pharmaceuticals has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Organogenesis presently has a consensus price target of $5.75, indicating a potential upside of 153.86%. Given Organogenesis' higher possible upside, equities research analysts plainly believe Organogenesis is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Organogenesis beats Telomir Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Get Telomir Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TELO vs. The Competition

Export

Metric	Telomir Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$84.26M	$2.99B	$6.76B	$12.50B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-4.22	18.55	26.93	24.41
Price / Sales	N/A	817.94	586.18	117.36
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	7.21	4.21	10.94	6.33
Net Income	-$10.41M	$64.26M	$3.58B	$330.66M
7 Day Performance	-1.21%	-3.32%	-2.10%	-0.66%
1 Month Performance	-2.78%	2.34%	3.21%	-0.14%
1 Year Performance	4.70%	20.50%	26.34%	20.16%

Telomir Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TELO Telomir Pharmaceuticals	0.5816 of 5 stars	$1.23 -1.2%	N/A	+6.9%	$84.26M	N/A	N/A	1
IRD Opus Genetics	3.0726 of 5 stars	$4.11 +1.4%	$10.77 +162.3%	+237.2%	$338.52M	$11.98M	N/A	14
SNDL SNDL	4.2423 of 5 stars	$1.32 +1.2%	$5.00 +280.2%	-5.8%	$338.48M	$677.32M	N/A	2,751	News Coverage Positive News
ELDN Eledon Pharmaceuticals	2.072 of 5 stars	$4.21 +7.0%	$9.67 +129.9%	+12.9%	$324.28M	N/A	N/A	10	Positive News
ALXO ALX Oncology	2.7166 of 5 stars	$2.39 +1.1%	$4.60 +92.9%	+308.3%	$322.27M	N/A	N/A	40	News Coverage Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TELO) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. IRD, SNDL, ELDN, ALXO, and ORGO

How does Telomir Pharmaceuticals compare to Opus Genetics?

Summary

How does Telomir Pharmaceuticals compare to SNDL?

Summary

How does Telomir Pharmaceuticals compare to Eledon Pharmaceuticals?

Summary

How does Telomir Pharmaceuticals compare to ALX Oncology?

Summary

How does Telomir Pharmaceuticals compare to Organogenesis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. IRD, SNDL, ELDN, ALXO, and ORGO

How does Telomir Pharmaceuticals compare to Opus Genetics?

Which has better valuation & earnings, TELO or IRD?

Does the media refer more to TELO or IRD?

Do insiders & institutionals hold more shares of TELO or IRD?

Which has more volatility and risk, TELO or IRD?

Is TELO or IRD more profitable?

Do analysts rate TELO or IRD?

Summary

How does Telomir Pharmaceuticals compare to SNDL?

Does the media prefer TELO or SNDL?

Do analysts rate TELO or SNDL?

Which has more risk & volatility, TELO or SNDL?

Is TELO or SNDL more profitable?

Which has preferable earnings & valuation, TELO or SNDL?

Summary

How does Telomir Pharmaceuticals compare to Eledon Pharmaceuticals?

Which has higher earnings & valuation, TELO or ELDN?

Does the media favor TELO or ELDN?

Do insiders and institutionals have more ownership in TELO or ELDN?

Do analysts prefer TELO or ELDN?

Which has more volatility and risk, TELO or ELDN?

Is TELO or ELDN more profitable?

Summary

How does Telomir Pharmaceuticals compare to ALX Oncology?

Do analysts prefer ALXO or TELO?

Do institutionals and insiders have more ownership in ALXO or TELO?

Which has stronger earnings and valuation, ALXO or TELO?

Is ALXO or TELO more profitable?

Does the media refer more to ALXO or TELO?

Which has more risk and volatility, ALXO or TELO?

Summary

How does Telomir Pharmaceuticals compare to Organogenesis?

Which has more volatility & risk, ORGO or TELO?

Which has better earnings & valuation, ORGO or TELO?

Does the media refer more to ORGO or TELO?

Do institutionals and insiders believe in ORGO or TELO?

Is ORGO or TELO more profitable?

Do analysts recommend ORGO or TELO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools